These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 19687150)

  • 21. A Hierarchical Multi-Unidimensional IRT Approach for Analyzing Sparse, Multi-Group Data for Integrative Data Analysis.
    Huo Y; de la Torre J; Mun EY; Kim SY; Ray AE; Jiao Y; White HR
    Psychometrika; 2015 Sep; 80(3):834-55. PubMed ID: 25265910
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An MCMC method for the evaluation of the Fisher information matrix for non-linear mixed effect models.
    Riviere MK; Ueckert S; Mentré F
    Biostatistics; 2016 Oct; 17(4):737-50. PubMed ID: 27166250
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modelling heterogeneity variances in multiple treatment comparison meta-analysis--are informative priors the better solution?
    Thorlund K; Thabane L; Mills EJ
    BMC Med Res Methodol; 2013 Jan; 13():2. PubMed ID: 23311298
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hierarchical Bayesian modeling of random and residual variance-covariance matrices in bivariate mixed effects models.
    Bello NM; Steibel JP; Tempelman RJ
    Biom J; 2010 Jun; 52(3):297-313. PubMed ID: 20544726
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparing hierarchical models via the marginalized deviance information criterion.
    Quintero A; Lesaffre E
    Stat Med; 2018 Jul; 37(16):2440-2454. PubMed ID: 29579777
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Markov chain Monte Carlo methods in biostatistics.
    Gelman A; Rubin DB
    Stat Methods Med Res; 1996 Dec; 5(4):339-55. PubMed ID: 9004377
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bayesian inference for stochastic multitype epidemics in structured populations using sample data.
    O'Neill PD
    Biostatistics; 2009 Oct; 10(4):779-91. PubMed ID: 19648227
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nonconjugate Bayesian analysis of variance component models.
    Wolfinger RD; Kass RE
    Biometrics; 2000 Sep; 56(3):768-74. PubMed ID: 10985214
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bayesian indirect and mixed treatment comparisons across longitudinal time points.
    Ding Y; Fu H
    Stat Med; 2013 Jul; 32(15):2613-28. PubMed ID: 23229717
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Markov chain Monte Carlo: an introduction for epidemiologists.
    Hamra G; MacLehose R; Richardson D
    Int J Epidemiol; 2013 Apr; 42(2):627-34. PubMed ID: 23569196
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bayesian multivariate meta-analysis with multiple outcomes.
    Wei Y; Higgins JP
    Stat Med; 2013 Jul; 32(17):2911-34. PubMed ID: 23386217
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bayesian adaptive Markov chain Monte Carlo estimation of genetic parameters.
    Mathew B; Bauer AM; Koistinen P; Reetz TC; Léon J; Sillanpää MJ
    Heredity (Edinb); 2012 Oct; 109(4):235-45. PubMed ID: 22805656
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The choice of prior distribution for a covariance matrix in multivariate meta-analysis: a simulation study.
    Hurtado Rúa SM; Mazumdar M; Strawderman RL
    Stat Med; 2015 Dec; 34(30):4083-104. PubMed ID: 26303671
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel Gibbs maximum a posteriori (GMAP) approach on Bayesian nonlinear mixed-effects population pharmacokinetics (PK) models.
    Kim S; Hall SD; Li L
    J Biopharm Stat; 2009 Jul; 19(4):700-20. PubMed ID: 20183435
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Application of the Bayesian dynamic survival model in medicine.
    He J; McGee DL; Niu X
    Stat Med; 2010 Feb; 29(3):347-60. PubMed ID: 20014356
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A general class of Bayesian survival models with zero and nonzero cure fractions.
    Yin G; Ibrahim JG
    Biometrics; 2005 Jun; 61(2):403-12. PubMed ID: 16011686
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modeling attainment of steady state of drug concentration in plasma by means of a Bayesian approach using MCMC methods.
    Jordan P; Brunschwig H; Luedin E
    Pharm Stat; 2008; 7(1):36-41. PubMed ID: 17335108
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A general joint model for longitudinal measurements and competing risks survival data with heterogeneous random effects.
    Huang X; Li G; Elashoff RM; Pan J
    Lifetime Data Anal; 2011 Jan; 17(1):80-100. PubMed ID: 20549344
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Network meta-analysis with competing risk outcomes.
    Ades AE; Mavranezouli I; Dias S; Welton NJ; Whittington C; Kendall T
    Value Health; 2010 Dec; 13(8):976-83. PubMed ID: 20825617
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incorporating data from various trial designs into a mixed treatment comparison model.
    Schmitz S; Adams R; Walsh C
    Stat Med; 2013 Jul; 32(17):2935-49. PubMed ID: 23440610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.